Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Toremifene in the treatment of breast cancer.
Mustonen MV, Pyrhönen S, Kellokumpu-Lehtinen PL. Mustonen MV, et al. World J Clin Oncol. 2014 Aug 10;5(3):393-405. doi: 10.5306/wjco.v5.i3.393. World J Clin Oncol. 2014. PMID: 25114854 Free PMC article. Review.
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, Garcia JA, Protheroe A, Tammela TL, Elliott T, Mattila L, Aspegren J, Vuorela A, Langmuir P, Mustonen M; ARADES study group. Fizazi K, et al. Lancet Oncol. 2014 Aug;15(9):975-85. doi: 10.1016/S1470-2045(14)70240-2. Epub 2014 Jun 25. Lancet Oncol. 2014. PMID: 24974051 Clinical Trial.
Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1.
Oksala R, Moilanen A, Riikonen R, Rummakko P, Karjalainen A, Passiniemi M, Wohlfahrt G, Taavitsainen P, Malmström C, Ramela M, Metsänkylä HM, Huhtaniemi R, Kallio PJ, Mustonen MV. Oksala R, et al. Among authors: mustonen mv. J Steroid Biochem Mol Biol. 2019 Sep;192:105115. doi: 10.1016/j.jsbmb.2018.02.004. Epub 2018 Feb 10. J Steroid Biochem Mol Biol. 2019. PMID: 29438723 Free article.
ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer.
Peltola KJ, Bono P, Jones RH, Vjaters E, Nykänen P, Vuorela A, Oksala R, Pohjanjousi P, Mustonen MVJ, Fizazi K, Massard C. Peltola KJ, et al. Among authors: mustonen mvj. Eur Urol Focus. 2020 Jan 15;6(1):63-70. doi: 10.1016/j.euf.2018.08.022. Epub 2018 Sep 5. Eur Urol Focus. 2020. PMID: 30194031 Free article. Clinical Trial.
Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours.
Bono P, Massard C, Peltola KJ, Azaro A, Italiano A, Kristeleit RS, Curigliano G, Lassen U, Arkenau HT, Hakulinen P, Garratt C, Ikonen T, Mustonen MVJ, Rodon JA. Bono P, et al. Among authors: mustonen mvj. ESMO Open. 2020 Dec;5(6):e001081. doi: 10.1136/esmoopen-2020-001081. ESMO Open. 2020. PMID: 33262202 Free PMC article. Clinical Trial.
Bone Scan Index and Progression-free Survival Data for Progressive Metastatic Castration-resistant Prostate Cancer Patients Who Received ODM-201 in the ARADES Multicentre Study.
Reza M, Jones R, Aspegren J, Massard C, Mattila L, Mustonen M, Wollmer P, Trägårdh E, Bondesson E, Edenbrandt L, Fizazi K, Bjartell A. Reza M, et al. Eur Urol Focus. 2016 Dec;2(5):547-552. doi: 10.1016/j.euf.2016.01.005. Epub 2016 Feb 3. Eur Urol Focus. 2016. PMID: 28723521 Free article.
Adrenals Contribute to Growth of Castration-Resistant VCaP Prostate Cancer Xenografts.
Huhtaniemi R, Oksala R, Knuuttila M, Mehmood A, Aho E, Laajala TD, Nicorici D, Aittokallio T, Laiho A, Elo L, Ohlsson C, Kallio P, Mäkelä S, Mustonen MVJ, Sipilä P, Poutanen M. Huhtaniemi R, et al. Among authors: mustonen mvj. Am J Pathol. 2018 Dec;188(12):2890-2901. doi: 10.1016/j.ajpath.2018.07.029. Epub 2018 Sep 28. Am J Pathol. 2018. PMID: 30273606 Free article.
29 results